Rockefeller Capital Management
SMMT icon

Rockefeller Capital Management’s Summit Therapeutics SMMT Stock Holding History

Rockefeller Capital Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$702 Buy
+37
New +$598 ﹤0.01% 4534
2025
Q4 		– Sell
-33
Closed -$682 – 4827
2025
Q3 		$682 Buy
+33
New +$800 ﹤0.01% 4230

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Rockefeller Capital Management's SMMT Position: Q1 2026 in Review

Rockefeller Capital Management opened a new position in Summit Therapeutics (SMMT) in Q1 2026: 37 shares worth $702. The stake represents ﹤0.01% of the portfolio and ranks #4534 among its holdings. This is a return to the name: Rockefeller Capital Management previously reported a position in SMMT as recently as Q3 2025.

Rockefeller Capital Management first reported a position in SMMT in Q3 2025 and has held it in 2 quarters since. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

  • Rockefeller Capital Management held 37 shares of Summit Therapeutics worth $702 as of Q1 2026.
  • Summit Therapeutics was a new Rockefeller Capital Management position in Q1 2026.
  • Summit Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #4534 holding.
  • Rockefeller Capital Management first reported a position in Summit Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.